Navigation Links
New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market
Date:6/17/2009

Sales of Acetylcholinesterase Inhibitors, Which Currently Dominate the Market, Will Decline by $1 Billion from 2008 to 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of new anti-amyloid monoclonal antibodies, most notably Elan/Wyeth's bapineuzumab and Eli Lilly's solanezumab, will be the main driver of robust 11 percent annual growth from 2008 to 2018 in the Alzheimer's disease drug market. Other key agents that will drive market growth include Baxter's Gammagard, Eli Lilly's semagacestat, and Pfizer/Medivation's Dimebon.

The new Pharmacor report entitled Alzheimer's Disease finds that bapineuzumab and solanezumab will together garner just over half of the overall Alzheimer's disease market in 2018. While these two monoclonal antibodies are expected to offer superior efficacy over other drugs in the market, their uptake will be initially slow following their launches, owing to potential safety concerns. Nevertheless, bapineuzumab and solanezumab will achieve combined sales of nearly $6 billion in 2018.

The Alzheimer's disease market is currently dominated by acetylcholinesterase inhibitors (AChEIs), all of which only address cognitive symptoms but do not modify the course of the disease. In 2008, sales of these agents for Alzheimer's disease (excluding other forms of dementia) accounted for $2.7 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan--in 2018, they will represent only $1.7 billion in sales, according to the report. This decline will be attributed to increased generic AChEI competition, overall market expansion driven by increases in the drug-treated population and the commercialization of emerging therapies with the potential to modify the progression of the disease.

"Interviewed experts believe that the agents with the most clinical and commercial promise are the anti-beta amyloid monoclonal therapies such as bapineuzumab and solanezumab, which have the potential to slow the rate of neurodegeneration and cognitive decline," said Decision Resources Analyst Matthew Winton, Ph.D. "However, the efficacy and safety of these monoclonal antibodies has yet to be fully established."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



    For more information, contact:

    Decision Resources                               Decision Resources, Inc.
    Christopher Comfort                              Elizabeth Marshall
    781-296-2597                                     781-296-2563
    ccomfort@dresources.com                          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Growth in the Parkinsons Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
2. Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform; All Demographics Report Personal Experience With the Disease
5. Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
6. New Report Emphasizes Critical Role of Including Early and Preventative Care for Women in Health Care Reform
7. The First High-Performance Sports Water, AquaHydrate, Targets Military Market by Supporting Events Including Mud Run
8. LOHAS Announces Final Program Line-up Including Speakers from Wal-Mart, Coca Cola, MINI, Facebook Causes, Saatchi & SaatchiS, Gaiam and eBay
9. MPR Drug Database Available as a Free Download for Mobile Devices, Including BlackBerry and Palm
10. Coalition Commends Senators Baucus, Grassley for Including Prevention, Wellness of Chronic Disease in Recent Paper on Coverage Policy Options
11. Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Todays Committee Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... ... 2018 , ... Liz Dudek, Director of Health Care Affairs for global law ... of the Florida Assisted Living Association (FALA) at 10:00 a.m. at Tessera of Brandon ... an overview of the success of the first five years of Florida’s Statewide Medicaid ...
(Date:9/22/2018)... ... September 21, 2018 , ... Located on the fourth floor ... new inpatient hospice unit on Monday, October 1. The 8,500 square-foot unit featuring 16 ... are excited to partner with an organization like TGH that provides excellent, innovative care,” ...
(Date:9/22/2018)... SAN LUIS OBISPO, Calif. (PRWEB) , ... September ... ... many different shapes and sizes. In fact, there are actually 29 different categories ... may qualify. These include charitable or religious organizations (often referred to as a ...
(Date:9/15/2018)... ... September 14, 2018 , ... ... healthcare industry, announced its live training initiative, "ShareNote Live" September, 17-18, 2018 at ... they can maximize its existing features and functionality in the midst of Louisiana’s ...
(Date:9/15/2018)... ... September 14, 2018 , ... Last night, Congressional leadership ... appropriations for Labor, Health and Human Services and Education (LHHS) and Defense. Specifically, ... (TPP) Program, and $286.5 million for the Title X Family Planning Program for ...
Breaking Medicine News(10 mins):
(Date:9/13/2018)... ... 2018 , ... This September is Centers for Disease Control and Prevention’s ... on how to help prevent food poisoning. According to the CDC, every year, an ... and 3,000 die from eating contaminated food. In support of the campaign, Best Sanitizers ...
(Date:9/13/2018)... ... September 13, 2018 , ... ... company focused on developing and commercializing gastrointestinal therapeutics, has secured acceptance of ... U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), have ...
(Date:9/12/2018)... ... September 12, 2018 , ... Lifetime Wellness , a leading ... the launch of a new online store to offer exclusive aromatherapy products to a ... “We’re thrilled to open our online store to offer our custom aromatherapy to not ...
Breaking Medicine Technology: